Study S000854

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Tolerability, Pharmacodynamics and Pharmacokinetics of ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov record

Registration

Registration: NCT05134662
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 55
Start: 2022-02-01
Primary completion: 2023-02-03
Lead sponsor: Altimmune, Inc.
Conditions: Type 2 Diabetes
Interventions: DRUG:ALT-801; OTHER:Placebo
Results posted: FALSE

Registered primary outcomes

The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs) [Up to Day 110]
Changes from baseline in area under the curve of serum glucose, C-peptide, and insulin [Baseline to Day 85]
Changes from baseline in fasting serum glucose and insulin as measured by Homeostasis Model Assessment for Insulin Resistance 2 (HOMA-IR2) [Baseline to Day 85]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.